{"id":"NCT03526549","sponsor":"Endo Pharmaceuticals","briefTitle":"Long-Term Study of EN3835 (CCH-aaes) in Edematous Fibrosclerotic Panniculopathy (Cellulite)","officialTitle":"A Phase 3b, Open-Label, Long-Term Study to Evaluate the Safety and Temporal Pattern of Response of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-04-26","primaryCompletion":"2021-10-08","completion":"2021-10-08","firstPosted":"2018-05-16","resultsPosted":"2023-09-08","lastUpdate":"2023-09-08"},"enrollment":483,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Edematous Fibrosclerotic Panniculopathy","Cellulite"],"interventions":[{"type":"BIOLOGICAL","name":"CCH-aaes","otherNames":["EN3835","QWOâ„¢"]},{"type":"OTHER","name":"Observation","otherNames":[]}],"arms":[{"label":"CCH-aaes Treatment in Parent Studies (EN3835-302/303)","type":"EXPERIMENTAL"},{"label":"Placebo Treatment in Parent Studies (EN3835-302/303)","type":"OTHER"}],"summary":"A Phase 3b, Open-Label Extension Study to evaluate safety and how long response of EN3835 (Collagenase Clostridium Histolyticum \\[CCH\\]-aaes) lasts in the treatment of Cellulite.","primaryOutcome":{"measure":"Number of Participants With Treatment-emergent Adverse Events (TEAEs)","timeFrame":"Up to Day 1080","effectByArm":[{"arm":"Day 180 Observation Phase: CCH-aaes Treatment in Parent Studies EN3835-302/303","deltaMin":58,"sd":null},{"arm":"Day 180 Observation Phase: Placebo Treatment in Parent Studies EN3835-302/303","deltaMin":29,"sd":null},{"arm":"Open-label Phase (Prior to Retreatment)","deltaMin":43,"sd":null},{"arm":"Open-label CCH-aaes Retreatment Phase","deltaMin":45,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":42,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":243},"commonTop":["Injection site bruising","Injection site discolouration","Injection site pain","Injection site pruritus","Corona virus infection"]}}